biotherapeutics quarterly - henry schein...likely to die from diabetes or liver diseases than...

Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News

Diagnostic and Pharmaceutical News for You and Your Medical Practice

Q u a r t e r l yBioTherapeutics

15MS3092

Volume 20/Summer 2015

Illustration: Human Liver

15MS3092_biotherapeutics_journal_vol.20.indd 1 7/23/15 11:03 AM

2BQ BioTherapeuticsQ u a r t e r l y

A Henry Schein Publication



3


The BioTherapeutics Quarterly Journal is published four times a year by Henry Schein, Inc. Henry Schein’s corporate headquarters are located at 135 Duryea Road, Melville, NY 11747. For journal sales information or to report corrections, e-mail [email protected] or call Kim Crabtree at 276-688-2090. Note that although we attempt to ensure the currency of the information contained in this publication as of the publication date, new biotherapeutic developments occur continually and, therefore, may not be noted in this publication. Not responsible for typographical errors.

BQ BioTherapeuticsQ u a r t e r l y


BQBioTherapeuticsQ u a r t e r l y

Volume 20/Summer 2015

Table of Contents5 A Letter to Henry Schein’s Valued Customers

6 MMWR: Increases in Hepatitis C Virus Infection Related to Injection Drug Use Among Persons Aged <30 years —Kentucky, Tennessee, Virginia, and West Virginia, 2006—2012

11 The ABCs of Hepatitis

13 New Drug Approvals

15 NIH Research Matters: Allergy Drug Treats Hepatitis C in Mice

18 NIH Research Matters: High-Resolution Imaging Technique May Advance Drug Design

20 National Institute of Mental Health: Depression in Children and Adolescents Fact Sheet

22 CDC Vital Signs: Hispanic Health

26 NIH: Colorectal Cancer Fact Sheet

30 MMWR Early Release: Melanoma Incidence and Mortality Trends and Projections —United States, 1982—2030

37 CDC VItal Signs: Preventing Melanoma

41 NIH: Prostate Cancer Fact Sheet


4 BQ BioTherapeuticsQ u a r t e r l y




A Letter to Henry Schein’sValued Customers




To provide health care professionals with a practical

and relevant source of information regarding

diagnostics, pharmaceuticals, and vaccines in a quick

and easy-to-read publication that provides educational

updates and insight to assist you in prevention,

diagnosis, and treatment of disease.

OUR Mission

Summer has arrived and as 2015 gains speed, the BioTherapeutics Quarterly journal strives to bring you the latest information on topics that are of interest to you, the healthcare practitioner. The BioTherapeutics Quarterly’s goal is to provide our loyal customers current, relative information on the prevention, diagnosis, and treatment of disease.

In this issue, we will be exploring several different topics including increases in Hepatitis C virus infection related to injection drug use, how high resolution imaging techniques may advance drug design, depression in children and adolescents, Hispanic health, colorectal cancer, melanoma incidence and mortality trends and projections, and prostate cancer.

There are an estimated 3.2 million people with chronic Hepatitis C virus infection and 75-85% of newly infected persons develop chronic infection. On page 12, the article MMWR: Increases

in Hepatitis C Virus Infection Related to Drug Use Among Persons Aged ≤30 Years – Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012 discusses surveillance data, which showed a substantial increase of 364% in the number of cases of acute HCV infection from 2006-2012. During 2006-2012, a total of 1,377 cases of acute HCV infection were reported to the CDC from these 4 states. There is currently no vaccine for Hepatitis C virus.

About 1 in 6 people living in the US are Hispanic. VitalSigns: Hispanic Health on page 22 discusses how heart dis-ease and cancer are the two leading causes of death, accounting for about 2 of 5 deaths. Hispanics are about 50% more likely to die from diabetes or liver diseases than whites. Hispanics in the US are on average nearly 15 years younger than whites, so steps Hispanics take now to prevent disease can go a long way towards a healthy future.

Skin cancer is the most common form of cancer in the United States, and melanoma is responsible for the most skin cancer deaths with over 9,000 each year. MMWR Vital Signs: Melanoma Incidence and Mortality Trends and Projections – United States, 1982-2030 on page 30 discusses the growing treatment costs, incidences, and projections through 2030. The rate of new cases of melanoma doubled from 1982-2011.

We hope you find the topics featured in this volume informative. If you have suggestions for future topics, please forward these to [email protected] and we will review your request.

Sincerely,

Kim CrabtreeDirector of Pharmaceuticals




Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I NewsDiagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News





Source: www.cdc.gov.mmwr/preview/mmwrhtml/mm6417a2.htm





Source:





NEW DRUG APPROVALS

May 27, 2015Viberzi™ (eluxadoline) TabletsTreatment for: Irritable Bowel SyndromeViberzi (eluxadoline) is a mu-opioid receptor agonist indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.Manufacturer: Actavis plc

May 21, 2015STiolTo™ reSpimaT (olodaterol and tiotropium) inhalation Spray Treatment for: Chronic Obstructive Pulmonary DiseaseStiolto Respimat (olodaterol and tiotropium bromide) is a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD). Manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc.

May 18, 2015inVega Trinza™ (paliperidone palmitate) extended-release injectable SuspensionTreatment for: SchizophreniaInvega Trinza (3-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia. Manufacturer: Janssen Pharmaceuticals, Inc.

April 30, 2015 TuziSTra™ Xr (chlorpheniramine polistirex and codeine polistirex) extended release oral Suspension Treatment for: Cold SymptomsTuzistra XR (codeine polistirex and chlorpheniramine polistirex) is an extended-release opiate agonist antitussive and histamine-1 (H1) receptor antagonist combination indicated for the relief of cough and symptoms associated with upper respiratory allergies or the common cold. Manufacturer: Vernalis plc and Tris Pharma Inc.

April 29, 2015 Kybella™ (deoxycholic acid) injection - formerly aTX-101 Treatment for: Submental FullnessKybella (deoxycholic acid) is a cytolytic drug indicated to improve the appearance of fullness associated with submental fat (double chin). Manufacturer: Kythera Biopharmaceuticals, Inc.

March 24, 2015 Quadracel® (diphtheria and Tetanus Toxoids and acellular pertussis absorbed and inactivated poliovirus; dTap-ipV Vaccine) injection Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Poliomyelitis Prophylaxis, Pertussis ProphylaxisQuadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) is a vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.Manufacturer: Sanofi Pasteur





Contact Us: 1.877.523.7468E-mail: [email protected]: www.henryschein.com/dxrxsolutions

Henry Schein’s DxRx Hotline is a single pointof contact for your organization for answersto various types of questions related to diagnostics, pharmaceuticals, and vaccines.

With a mission of helping practices diagnose,prevent, and treat disease, the DxRx team isavailable as a trustworthy and accessiblesource of information at your convenience.

The DxRx team is availablevia phone, e-mail, and Live Chat,8 am–6 pm, et.

FEATURES:DxRx can answer questions related to:

• Latest updates on supply issues

• Indications and usage as provided on package inserts

• Brand-to-generic conversions

• CPT® and J codes*

• CLIA product status

• Product storage requirements

• ACIP recommendations for vaccinations

• Flu vaccine and �u-related topics

*For informational purposes only.Source: www.reimbursementcodes.com or www.cms.gov.Customer is responsible for veri�cation of billing/coding inaccordance with applicable speci�c circumstance.

BENEFITS: • Expedite diagnosis and treatment at the point of care • Free, on-demand resource for immediate needs • Easy-to-access and use resource • One phone call to answer pharmaceutical, diagnostic, and vaccination questions • Live support with no automation

Make one call or e-mail to our diagnostics, pharmaceutical, and vaccine expertsand let us do the research –it’s better than a PDR for point-of-care assistance.

CLINICAL

Source: www.nih.gov/researchmatters/april2015/04202015hepatitis.htm





Source: www.nih.gov/researchmatters/june2015/06012015imaging.htm





Source: www.nami-pa.org





Source:





Source: www.report.nih.gov





These services will help you contain costs and increase profitability.

Save your patients hundreds of dollars on medication with our exclusive pharmaceuticals discount card.

rx pHarmacy diScounT card*

Call: 1.877.581.4526Visit: www.henryschein.com/usarx

Rx BIN: 011867Rx PCN: HT

Member ID: 9999999Rx GROUP: USARX99999

PHARMACY DISCOUNT CARD

Save up to 75% on all FDA-approved medicationsUse this card on brand and generic medications.

You will not be turned down for pre-existing conditions. No pre-approval needed. This is not insurance.

*Henry Schein may receive a marketing fee from the vendor from products/services purchased





Source:





in-office rx diSpenSing

These services will support revenue generation and the expansion of services in your facility.

Sampling program

A free and secure online service for Eligible* prescribers.

Increase patient compliance: 30% of patients fill a Rx only when provided a sample, regardless of their age, income or gender***Only eligible prescribers are able to enroll and order samples through the Henry Schein Rx Samples Service.Prescribers can check their eligibility by calling or visiting the website.

**Source: Datamonitor

Call: 1.866.772.1580Visit: www.hsrxss.com

Dispense prepackaged medications to improve patient health, lower costs and enhance revenue streams.

Stocking 30–50 of your most commonly prescribed generic medications will cover approximately 80% of patient needs.

Call: 1.877.523.7468Visit: www.henryschein.com/rxdispensing





Source:





Source: www.report.nih.gov





For more information visit: www.henryschein.com/acnizil

neW!

“Acne is very common during pregnancy but there are very few safe treatment options as many prescription and over the counter products should not be taken while pregnant. Acnizil is a great alternative to antibiotics. It is a safe and effective way for patients to manage acne while they are pregnant.” Michael Swor, MD, OB/GYN

EXCLUSIVE!

(856-0011) Acnizil™ 1.5 oz. Tube (12/Case)

Acnizil™ is formulated with a proprietary and patented nanoparticulate silver clinically proven to kill the Propionibacterium acnes (P. acnes) bacteria. Acnizil™ does not require a prescription & can be used on mild, moderate & severe acne.

Are You Still Using Technology From The 1970s? Not Likely! So why aren’t you recommending the NEW technology silver?

Protect Your Patients Against Community Acquired InfectionsReimbursed as a hydrogel using HCPCS code A6248†

SilvrSTaT® (rx) antibacterial Wound dressing gel (685-0183)..............................................................1 oz. (685-0184)..............................................................3 oz.

*Caution: Federal law restricts the sale of this device by, or on the order of, a licensed health care practitioner. †For informational purposes only. Source: ABL Medical, LLC. Customer is responsible for verification of billing/coding in accordance with applicable specific circumstances.

beST Value Save 30% vs the 1 oz. size!

• MRSA is one of the most troubling health care concerns causing over 94,000 hospitalization and 18,000 deaths per year • SilvrSTAT* is the only multivalent silver FDA-indicated to inhibit MRSA! • SilvrSTAT is a NEW type of silver that immediately and continuously kills harmful bacteria • Water based – no alcohol, alginate or sulfa. No known adverse events. • SilvrSTAT is indicated for the management of skin tears, lacerations, abrasions, 1st and 2nd degree burns, wounds such as stasis ulcers, pressure ulcers, diabetic ulcers, surgical incision sites, device insertion


Call: 1-800-P-SCHEIN

(1-800-772-4346) 8am–8:30pm (et)

Fax: 1-800-329-9109

24 Hours

www.henryschein.com/medical©2015 Henry Schein, Inc. No copying without permission.

Not responsible for typographical errors.

15MS3092

Call your Henry SCHein SaleS ConSultant For additional detailS!


biotherapeutics quarterly - henry schein...likely to die from diabetes or liver diseases than...

Documents